Recursion Pharmaceuticals (RXRX) is back in focus after reporting fourth quarter and full year 2025 results, highlighting much higher quarterly revenue, a smaller net loss, and fresh commentary on its ...

Need a quote from a Motley Fool analyst? Over the past decade, Recursion Pharmaceuticals, Inc. has built something truly special: a differentiated platform pioneering the integration of large-scale ...

Ricursive Intelligence, founded by two former Google researchers and valued at $4 billion, is among several efforts to automate the creation of artificial intelligence. Anna Goldie and Azalia ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

Great leadership doesn’t just happen in boardrooms or business settings. From little league coaching and community initiatives to family moments and encounters with service providers, powerful ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

Christopher Gibson, Chief Executive Officer of Recursion Pharmaceuticals, recently sold a significant chunk of his company's common stock. The CEO of Recursion Pharmaceuticals recently disposed of 120 ...